Evidence map›Paper›PMID 41281636›Full record

ArticleMaterials today. Bio2025

Urine-derived stem cells efficiently assemble into micro-bone organoids supported by decellularized bone matrix microparticles for rapidly repairing bone defects through direct filling and paracrine functions.

Yiting Chen, Liang Zhang, Zeyu Li, Xinrun Wang, Jie Liu, Xianwen Wang, Jiyun Hu, Guotao Wang, Qihang Huang, Yuhao Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yiting ChenDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Liang ZhangDepartment of Orthopedic Trauma, Chenzhou No. 1 People's Hospital, Chenzhou, Hunan, 423000, China.
Zeyu LiDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Xinrun WangDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jie LiuDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Xianwen WangDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jiyun HuDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Guotao WangDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Qihang HuangDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Yuhao YuanDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The repair of large bone defects remains a significant challenge in orthopedic clinical practice. This study aims to rapidly cultivate a novel type of bone organoids (BOs), namely uBOs (USCs@DBM-MPs derived BOs), by utilizing self-developed highly biomimetic decellularized bone matrix microparticles (DBM-MPs) as the supporting carrier in combination with non-invasively obtained urine-derived stem cells (USCs), and to explore its therapeutic efficacy and biological mechanism. In our vitro experiments confirmed that DBM-MPs exhibit excellent biocompatibility and osteoinductivity, and urine-derived stem cells (USCs) have comparable osteogenic potential to bone marrow stem cells (BMSCs). Furthermore, USCs were loaded onto DBM-MPs for osteogenic directional induction, and a novel bone organoid-uBOs, was successfully generated within 14 days. Meanwhile, compared with bBOs (BMSCs@DBM-MPs derived BOs), uBOs exhibit comparable levels of biological activity, proliferation characteristics, and osteogenic potential. Moreover, uBOs offer the advantages of a broader availability and a non-invasive acquisition process. What is particularly noteworthy is that these uBOs exhibit paracrine functions capable of promoting both angiogenesis and osteogenesis. In-vivo rat femoral condyle defect model, minimally invasive injection of uBOs into the bone defect area achieved rapid bone regeneration within only 6 weeks, perfectly repairing the defect area. The uBOs developed in this study not only as a bone substitute unit for direct filling and repair of bone defects, but also continuously induce angiogenesis and bone fusion at the defect site through their paracrine mechanism, offering a brand-new and efficient tissue engineering strategy for bone defect treatment.

Indexed as

Bone defectBone organoidDecellularized bone matrixParacrine functionsUrine-derived stem cells

Identifiers

PMID41281636
PMCPMC12639860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.